Evidence map›Paper›PMID 31594465›Full record

ArticleOpen biology2019

miR-149-3p reverses CD8

Meng Zhang, Dian Gao, Yanmei Shi, Yifan Wang, Rakesh Joshi, Qiongfang Yu, Daheng Liu, Faizah Alotaibi, Yujuan Zhang, Hongmei Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Posttranscriptional Events Orchestrate Immune Homeostasis of CD8Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  19. CD8Frontiers in immunology · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Meng ZhangInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Dian GaoDepartment of Pathogen Biology and Immunology, Medical College of Nanchang University, Nanchang 330006, People's Republic of China.
Yanmei ShiInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Yifan WangInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Rakesh JoshiDepartment of Surgery, Western University, London, Canada N6A 5A5.
Qiongfang YuDepartment of Gastroenterology and Hepatology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, People's Republic of China.
Daheng LiuDepartment of Surgery, Western University, London, Canada N6A 5A5.
Faizah AlotaibiDepartment of Surgery, Western University, London, Canada N6A 5A5.
Yujuan ZhangInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Hongmei WangInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Qing LiDepartment of Gastroenterology and Hepatology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, People's Republic of China.
Zhu-Xu ZhangInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
James KoropatnickDepartment of Surgery, Western University, London, Canada N6A 5A5.
Weiping MinInstitute of Immunotherapy of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang 330006, People's Republic of China.
Western University · CANanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blockade of inhibitory receptors (IRs) is one of the most effective immunotherapeutic approaches to treat cancer. Dysfunction of miRNAs is a major cause of aberrant expression of IRs and contributes to the immune escape of cancer cells. How miRNAs regulate immune checkpoint proteins in breast cancer remains largely unknown. In this study, downregulation of miRNAs was observed in PD-1-overexpressing CD8

Indexed as

3' Untranslated RegionsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCells, CulturedCytokinesFemaleForkhead Transcription FactorsHepatitis A Virus Cellular Receptor 2ImmunotherapyMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMicroRNAsProgrammed Cell Death 1 ReceptorReceptors, Immunologic3' Untranslated RegionsBTLA protein, mouseCytokinesForkhead Transcription FactorsFoxp1 protein, mouseHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2MicroRNAsMIRN149 microRNA, mousePdcd1 protein, mouseProgrammed Cell Death 1 ReceptorReceptors, ImmunologicRepressor Proteinsbreast cancerimmunotherapymir-149-3pPD-1T-cell exhaustion

Identifiers

PMID31594465
PMCPMC6833224
OpenAlexW2980270483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.